Viking Therapeutics Inc
VKTX
NASDAQ
Biotechnology
$33.19
USD
+0.25 (+0.76%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.93B
Volume 1.2M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-534.80M
TTM
-211.7%
YoY
Operating Cash Flow
$-418.44M
TTM
-174.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 14.4 | 8.6 | 11.3 | 14.0 | 16.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 74.6 | 98.6 | 164.7 | 164.1 | 132.6 |
Operating Income | -74.6 | -98.6 | -164.7 | -164.1 | -132.6 |
EBITDA | -74.6 | -98.6 | -164.7 | -164.1 | -132.6 |
Other Income / Expense | -0.0 | 0.0 | -0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 9.0 | 7.8 | 7.1 | 5.8 | 4.6 |
Income Before Income Taxes | -65.6 | -90.8 | -157.7 | -158.3 | -128.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -65.6 | -90.8 | -157.7 | -158.3 | -128.0 |
Consolidated Net Income / Loss | -65.6 | -90.8 | -157.7 | -158.3 | -128.0 |
Net Income Attributable to Common Shareholders | -65.6 | -90.8 | -157.7 | -158.3 | -128.0 |
Basic EPS | -$0.58 | -$0.81 | -$1.38 | -$1.37 | -$1.10 |
Diluted EPS | -$0.58 | -$0.81 | -$1.38 | -$1.37 | -$1.10 |
Basic Shares Outstanding | 112.1M | 112.3M | 114.1M | 115.6M | 116.3M |
Diluted Shares Outstanding | 112.1M | 112.3M | 114.1M | 115.6M | 116.3M |